HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Trial design, clinician advocacy key to acceleration of research, review processes
-
- Bevacizumab, carboplatin, paclitaxel combination safe, active in ovarian cancer
- Similar outcomes observed after radiotherapy in whites, blacks with HNSCC
- Targeted therapy improved OS in metastatic RCC
- Assisted conception did not increase cancer risk in children
- Better QoL with radioembolization treatment than TACE among HCC patients
- Childhood HSCT increased risk for kidney stones
- High TIL grade inversely associated with mortality in primary melanoma
- Hypertension increased cardiac event risk among childhood cancer survivors
-
- Radiation therapy plus surgery extended OS in metastatic rectal cancer
- Ramucirumab improved survival for gastric, gastroesophageal junction adenocarcinoma
- Adjuvant radiation therapy provided superior local control in desmoplastic melanoma
- PFS2 evaluation reveals benefit of lenalidomide in multiple myeloma
- Anti-CD19 CAR T cells effective in advanced B-cell lymphoma
- Developmental mutation identified in gray platelet syndrome
- Early surgery for stage IV breast cancer failed to improve OS
- Exercise alleviated arthralgia pain in breast cancer survivors by 30%
-
- Novel gene therapy prompted T-cell recovery in SCID-X1
- TSH suppression after thyroidectomy increases osteoporosis risk in women
- Lenalidomide maintenance extends PFS in multiple myeloma after transplantation
- Transplant rates improved among ethnic minorities
- Elderly patients tolerated reduced-intensity, related haploidentical BMT followed by high-dose cyclophosphamide
- Pediatric palliative care: A year in review for oncologists Christine A. Zawistowski, MD